

The objectives of the Strategy are to:

- 1. support a **research culture** in NHMRC-funded institutions that is conducive to the conduct of high quality research
- 2. support **high quality** in the development, design, methodology, conduct and analysis of NHMRC-funded research
- 3. support transparency of NHMRC-funded research
- 4. support **accountability** for high quality research by NHMRC-funded institutions and their institutional review committees
- 5. ensure the need for incremental and breakthrough innovations is balanced with the need for necessary replication, and
- 6. ensure NHMRC's processes are **efficient** while supporting high quality research.





Status update

 Draft NHMRC Research Quality Strategy (the Strategy) developed by Research Quality Steering Committee (July 2018-Feb 2019).
 Consideration by NHMRC's Research Committee and Council (March 2019).

Phase 1

CEO approval and release of the Strategy (mid-2019).

Phase 1-Early initiatives

 Research Quality Steering Committee and its subgroups progressing early initiatives identified during the development of the Strategy (July 2018 - Ongoing).

Phase 2

- · Ongoing consultation and engagement with the sector about implementation of the Strategy.
- · Progression of activities and tasks identified in the Strategy and associated Action Plan.
- · Ongoing consultation with national and international agencies and partners.

Outline

- 1. The problems
- 2. NHMRC & International plans
- 3. Today's workshop themes

Spectrum of research practices

How it should be done:

Relevant, Valid, Reproducible, Efficient

Sloppy science:

Ignorance, honest error or dubious integrity

Scientific fraud:

Fabrication, Falsification, Plagiarism

Responsible Conduct of Research

Questionable Research Practices

Research Misconduct

Lex Bouter, VMC, Netherlands

Begley's Bombshell

Between 2002-2012, Amgen was not able to reproduce the seminal findings from 47 of 53 "top tier" publications.

- publications that reported something completely "new"

The major finding was not reproduced!


In the majority, data was <u>not</u> reproduced by the original investigators <u>with their reagents in their lab</u>

Amgen's experience is not unique....

COMMENT

avian influenza Shift experto track mutations who

give valuable clues to full warming n 537 history of science Descarte lost letter tracked using Google 9 540 OBITUARY Wylie Vale and an elusive stress hormone p.542



Raise standards for preclinical cancer research

C. Glenn Begley and Lee M. Ellis propose how methods, publications and incentives must change if patients are to benefit.

If forts over the past decade to characterize the genetic alterations in human cancers have led to a better understanding of molecular drivers of this complex set of diseases. Although we in the cancer field hoped that this would lead to more effective drugs, historically, our ability to translate cancer research to clinical success has been remarkably low. Sadly, clinical succ

trials in oncology have the highest failur rate compared with other therapeutic area Given the high unmet need in oncology; is understandable that barriers to clinical development may be lower than for othe disease areas, and a larger number of drug with suboptimal preclinical validation wi enter oncology trials. However, this lows us corrected by a more present that the present of the control of the present of the present of the present of the control of the present of the present of the present of the present control of the present of the investigators must reassess their approach to translating discovery research into greater clinical success and impact.

Many factors are responsible for the high failure rate, notwithstanding the inherently difficult nature of this disease. Certainly, the limitations of preclinical tools such as inadequate cancer-cell-line and mouse models' make it difficult for even >

29 MARCH 2012 | VOL 483 | NATURE | 53 2 Macmillan Publishers Limited. All rights reserved

A very brief history

1994 - "huge sums of money are spent annually on research that is seriously flawed through the use of inappropriate designs, unrepresentative samples, small samples, incorrect methods of analysis, and faulty interpretation"

Doug Altman, The Scandal of Poor Medical Research, BMJ.




2012 Begley & Ellis - Amgen not able to reproduce the seminal findings from 47of 53 "top tier" publications (reproducibility crisis)


2014 Lancet 5-part series on Adding Value, Avoiding Waste published

2014 Ensuring Value in Research (EVIR) funders forum initiated

2018 NHMRC Research Quality Committee set up







Annual avoidable waste in research estimated to be 85% from:


- avoidable design flaws (50%),
- 4. non-publication (50%) and
- 5. unusable reports (50%)
- for a global total of over \$140 Billion/year.

Calculation at: http://blogs.bmj.com/bmj/2016/01/14/paul-glasziou-and-iain-chalmers-is-85-of-health-research-really-wasted/

Adding Value, Reducing Waste Lancet Series 2014 www.researchwaste.net



50% of research is not published




Lancet 2014;383:257-66



Poor reporting of non-pharmacological interventions in 6 major medical journals






Of 133 trials in 2010

59% adequate after contacting author

39% adequate in primary sources

Unavoidable "waste" in research



"Young man, why would I feel like a failure? And why would I ever give up? I now know definitively over 2,000 ways that an electric light bulb will not work. Success is almost in my grasp."

Thomas Edison

99% perspiration

1% innovation

- EVIR funders forum
- EQUATOR network
- Hong Kong Principles
- Open Science Framework



The next EViR Forum meeting will be held in Dublin (Health Research Board offices) on the 28-29 March 2019.

Details to follow on this website or contact **EViRFundersForum@gmail.com** for more information

Organisations from around the world are coming together to advance the practices of health related research and research funding, in order to increase the value of health related research.

The Ensuring Value in Research (EViR) Funders' Collaboration and Development Forum started in 2017, with meetings in London, Den Haag and Washington DC. In our first year the Funders' Forum developed a Consensus Statement and Guiding Principles.


As organisations that fund health-related research, represent funders, or set funding policy, we have a responsibility not just to seek to advance knowledge, but also to advance the practices of health-related research and research funding. Through working together and with our respective research communities we are sharing current and developing new approaches to increase the value of health-related research.

Delegates from eight countries have attended meetings so far, with the next meeting of the EViR Funders' Forum taking place in Cardiff, Wales, UK on 16-17 May 2018.


Members of the forum who have already endorsed the consensus statement and guiding principles include:

- Forte (Sweden)
- Graham Boeckh Foundation
- Health and Care Research Wales Welsh Government (UK)
- Health Research Board Ireland (Ireland)
- Marie Curie (UK)
- Ministry of Health Salute (Italy)
- NIHR National Institute for Health Research (UK)*
- PCORI Patient Centered Outcomes Research Institute (USA)


- EVIR funders forum
- EQUATOR network
- Open Science Framework
- Hong Kong Principles



- EVIR funders forum
- EQUATOR network
- Open Science Framework
- Hong Kong Principles



- EVIR funders forum
- EQUATOR network
- Open Science Framework
- Hong Kong Principles



What to change?

- 1. Blinding, blinding, blinding
- 2. Good reporting
- 3. Study registration
- 4.


99. Lack of computing power 100. Spelling mistakes

How to change it?

Strategy for Culture Change

June 11th, 2019, Brian Nosek

Tags: Behavior Change, Open Science, Reproducibility, Culture Change




NHMRC Research Quality Steering Committee

Terms of Reference:

- Advise NHMRC's CEO on mechanisms for enhancing quality in NHMRC-funded research through rigour, transparency and reproducibility, including:
 - identification of factors that enable or hinder rigour,
 transparency and reproducibility in research
 - short and long-term strategies for improving rigour, transparency and reproducibility in NHMRC-funded research, and
 - measuring and reporting effectiveness of strategies.

Where are we now?



Education & Training

Curriculae



Training processes

COMMENTARY

Open Access



Designing integrated research integrity training: authorship, publication, and peer review


Mark Hooper * 6, Virginia Barbour, Anne Walsh, Stephanie Bradbury and Jane Jacobs

Table 1 Authorship and Publication agenda

#	ltem	Method of delivery
1	Welcome, overview, etc.	Narrator introduction
2	Develop a data management plan	Lightning talk
3	Get an ORCID iD	Lightning talk
4	Agree authorship	Lightning talk
5	Academics discussing authorship	Video (short interview clips)
6	Shortlisting journals	Lightning talk
7	Open access 101	Lightning talk
8	Writing tips	Video (short interview clips)
9	Originality and plagiarism	Lightning talk
10	Report COIs and acknowledge grants	Video (animated)
11	Do you still need a cover letter?	Lightning talk
12	Respond to peer review	Video (animated)
13	Review the publishing agreement	Lightning talk
14	Deposit manuscript at QUT ePrints	Lightning talk
15	What happens after publication?	Lightning talk
16	Promote your work	Lightning talk
17	Questions	Open discussion

Infrastructure & Tools

Tools to aid better study design




Click here to access the EDA






Trial registration



Institutional Support




UK Reproducibility Network



UKRN Activities

- Registered Reports
- Registered Reports Funding
- Editors4BetterResearch
- Accountable Replication Policies
- Octopus
- Open Research Working Groups
- ReproducibiliTea
- Hiring Policies Certification Scheme
- <u>Laboratory Efficiency Assessment Framework (LEAF)</u>



Research on Research

Research on Research Problems



Research on Research Efficiency

Home / Resources / Studies Within a Trial

Studies Within a Trial (SWAT)

Our colleagues at Queen's University Belfast host the Studies Within a Trial (SWAT) and Studies Within a Review (SWAR) initiative (site).

It is being developed by the Northern Ireland Network for Trials Methodology Research in collaboration with the Medical Research Council's Network of Hubs for Trials Methodology Research in the UK (HTMR Network), the Health Research Board's Trials Methodology Research Network in Ireland (HRB-TMRN), and others.

More information, and a repository of existing SWATs can be found at the site. If you are interested in embedding methodology research into an ongoing trial and other prospective study, have a look at the SWAT (Studies Within A Trial) collection online to see examples, or to register a new SWAT.











www.qub.ac.uk/sites/The Northern Ireland Network for Trials Methodology Research/SWATSWAR Information/SWATSWAR I

 \wedge